Canal de iões

<p>Vanilloid receptor 1 antagonist</p>

<p>Potassium channel blocker; antiarrhythmic agent</p>

<p>GABAA receptor antagonist that displaces [3H]-GABA in membranes of rat brain (Ki value 0.15 µM). Has greater affinity for GABAA than bicuculline (20-fold greater). Inhibits Cl- current induced by GABA, but not pentobarbitone. Low-affinity inhibitor of glycine receptors.</p>

<p>Voltage-dependent K+ channel opener; insulinotropic sulfonylurea receptor ligand</p>

<p>Oxcarbazepine metabolite; anticonvulsant; sodium channel blocker</p>

<p>Amlodipine is a calcium channel blocker that is used to treat hypertension and angina. This drug inhibits the influx of calcium ions into both vascular smooth muscle and cardiac muscle.</p>

<p>Nateglinide is used to treat type 2 diabetes mellitus as an oral hypoglycemic, insulinotropic agent. It is a blocker of ATP-dependent potassium channels and works by increasing the body's production of insulin, which lowers blood glucose levels. Nateglinide has been shown to be effective in reducing postprandial blood glucose levels in patients with type 2 diabetes who have not responded well to other treatments. The effects of nateglinide are reversible.</p>

<p>Amiodarone a class III anti-arrhythmic agent, used to treat and prevent certain types of irregular heartbeats. It is a competitor for natural ligands of alpha and beta adrenergic receptors, muscarinic acetylcholine receptors, histamine H1 receptors, and serotonin 5HT2A/5HT2C receptors. Amiodarone has been shown to reduce the number of atrial and ventricular arrhythmias in patients with structural heart disease, and has been used to treat atrial fibrillation, ventricular tachycardia, and Wolff-Parkinson-White Syndrome. It has also been used in the prevention of myocardial infarcts due to its ability to modify blood pressure and maintain cardiac function. In addition, amiodarone inhibits prostaglandin synthesis by inhibiting cyclooxygenase enzymes. This prevents inflammation in the gastrointestinal tract and reduces bowel disease symptoms such as cramping or diarrhea.</p>

<p>NBQX is a competitive antagonist of ionotropic glutamate receptors of AMPA and kainate subfamilies. It has been reported anti-convulsant activity in seizures models induced by electrostimulation, drugs or genetic predisposition.</p>

<p>Aminosteroid; neuromuscular blocker in anaesthetics</p>

<p>Acamprosate is a drug that has been shown to have a synergic effect in the treatment of alcohol dependence. It is a structural analogue of the neurotransmitter gamma-aminobutyric acid (GABA). Acamprosate works by binding to glutamate receptors and inhibiting the release of glutamate, which may help restore the balance between excitatory and inhibitory neurotransmitters in the brain. Acamprosate also has a protective effect on brain cells by inhibiting protein synthesis and increasing the production of glutathione, which acts as an antioxidant.</p>

<p>Antagonist of NMDA glutamate receptor at glycine binding site</p>

<p>Potassium channel blocker; anti-arrhythmic; cardiac depressant</p>

<p>Benidipine is a synthetic dihydropyridine calcium channel blocker. This drug is used in the treatment of coronary heart diseases, hypertension, and angina pectoris. Benipidine binds to the L-type voltage-gated calcium channels and blocks their opening which leads to smooth muscle relaxation and a decrease in blood pressure.</p>

<p>Inhibits cardiac late sodium channel current; antiarrhythmic</p>

<p>Suzetrigine is a novel compound classified as a synthetic ligand, which is derived through advanced chemical synthesis techniques. This compound engages specific targets within biological systems, acting primarily as a selective modulator of ion channels.</p>

<p>Sodium channel blocker; anti-arrhythmic agent</p>

<p>Inhibitor of TASK tandem pore potassium channel; respiratory stimulant</p>

<p>Antagonist of serotonin receptors 5-HT3</p>

<p>Inhibitor of voltage-activated calcium channels</p>